title: Novel CD9-targeted therapies in gastric cancer.
abstract: There are 33 human tetraspanin proteins, emerging as key players in malignancy, the immune system, fertilization, cellular signaling, adhesion, morphology, motility, proliferation, and tumor invasion. CD9, a member of the tetraspanin family, associates with and influences a variety of cell-surface molecules. Through these interactions, CD9 modifies multiple cellular events, including adhesion, migration, proliferation, and survival. CD9 is therefore considered to play a role in several stages during cancer development. Reduced CD9 expression is generally related to venous vessel invasion and metastasis as well as poor prognosis. We found that treatment of mice bearing human gastric cancer cells with anti-CD9 antibody successfully inhibited tumor progression via antiproliferative, proapoptotic, and antiangiogenic effects, strongly indicating that CD9 is a possible therapeutic target in patients with gastric cancer. Here, we describe the possibility of CD9 manipulation as a novel therapeutic strategy in gastric cancer, which still shows poor prognosis.
authors: Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan.
authors: Yoko
authors: Y
authors: Murayama
authors: Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan.
authors: Kenji
authors: K
authors: Oritani
authors: Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan.
authors: Shusaku
authors: S
authors: Tsutsui
mesh_terms: D000818:Animals; D000906:Antibodies / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D060245:Tetraspanin 29 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; C554869:CD9 protein, human; D060245:Tetraspanin 29
keywords: CD9; Gastric cancer; Tetraspanin; Therapeutic target; Tumorigenicity